cytomegalovirus-specific cytotoxic t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 3, 2015 (NCT02210065)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cytomegalovirus-specific cytotoxic t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05564598 | Phase 2 | Jul 1, 2023 | New York Medical College |
| NCT03010332 | N/A | Jan 3, 2017 | Atara Biotherapeutics |
| NCT02210065 | Phase 2 | Mar 3, 2015 | Miltenyi Biotec, Inc., University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atara Biotherapeutics | For profit | 1 | 1 | 1 | 2017 |
| Miltenyi Biotec, Inc. | For profit | 1 | 0 | 1 | 2015 |
| New York Medical College | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2015 |
4 organizations
Page 1 / 1